uniQure (NASDAQ:QURE) Shares Gap Up – Still a Buy?

uniQure N.V. (NASDAQ:QURE)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $26.99, but opened at $43.55. uniQure shares last traded at $47.4490, with a volume of 6,117,597 shares trading hands.

Analysts Set New Price Targets

A number of brokerages have issued reports on QURE. Sanford C. Bernstein downgraded uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Leerink Partners reissued an “outperform” rating and issued a $35.00 price target on shares of uniQure in a research note on Monday, March 2nd. Barclays cut their price target on shares of uniQure from $31.00 to $25.00 and set an “equal weight” rating for the company in a report on Monday, March 23rd. Finally, HC Wainwright decreased their price objective on shares of uniQure from $70.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Ten equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.83.

uniQure Trading Up 72.8%

The stock has a market capitalization of $2.94 billion, a PE ratio of -13.36 and a beta of 0.98. The company’s 50 day moving average price is $22.93 and its two-hundred day moving average price is $21.75. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.03. The company had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. As a group, analysts expect that uniQure N.V. will post -3.64 earnings per share for the current year.

Insider Buying and Selling at uniQure

In related news, Director Robert Gut sold 7,552 shares of uniQure stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $26.05, for a total transaction of $196,729.60. Following the transaction, the director owned 27,435 shares in the company, valued at approximately $714,681.75. This trade represents a 21.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack Kaye sold 2,645 shares of the business’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $30.01, for a total value of $79,376.45. Following the transaction, the director directly owned 20,439 shares in the company, valued at $613,374.39. This trade represents a 11.46% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 85,817 shares of company stock worth $2,232,383. 4.65% of the stock is owned by company insiders.

Institutional Trading of uniQure

Hedge funds and other institutional investors have recently modified their holdings of the stock. Torren Management LLC purchased a new position in shares of uniQure during the 4th quarter worth $28,000. Jones Financial Companies Lllp grew its holdings in shares of uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares during the period. IFP Advisors Inc acquired a new stake in uniQure during the fourth quarter worth about $48,000. Smartleaf Asset Management LLC acquired a new stake in uniQure during the fourth quarter worth about $48,000. Finally, CIBC Private Wealth Group LLC purchased a new position in uniQure during the third quarter worth about $50,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.